Acrobat Genomics
Acrobat Genomics is a Stanford drug-discovery spinout and public benefit corporation at MBC BioLabs in San Carlos, CA.
About
Acrobat Genomics is a Stanford drug-discovery spinout and public benefit corporation at MBC BioLabs in San Carlos, CA. Its AcrobaTx Engine pairs AI-proposed gene-editor, inhibitor and protein designs with high-throughput functional screening in human cells in a closed loop. It is a prime contractor on DARPA's RIDDL program, NIH-funded, and an Illumina Accelerator 2022 company.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Acrobat Genomics
Acrobat Genomics is a Stanford drug-discovery spinout and public benefit corporation at MBC BioLabs in San Carlos, CA. Its AcrobaTx Engine pairs AI-proposed gene-editor, inhibitor and protein designs with high-throughput functional screening in human cells in a closed loop. It is a prime contractor on DARPA's RIDDL program, NIH-funded, and an Illumina Accelerator 2022 company.
—
United States
BusinessLatest roundTotal raisedDate- Onava
Onava is an AI-native biotech company in San Carlos, California, building an agentic, lab-in-the-loop antibody discovery platform that couples generative AI and ML-driven protein engineering with proprietary high-throughput functional assays to design potent, developable therapeutic antibodies against hard targets.
— - BigHat Biosciences
AI design of antibody and protein drugs
Series C · $223M · 2026-09
$223M - Tahoe Therapeutics
Develops large-scale single-cell datasets to train AI models of human cells for drug discovery
Undisclosed · $30M · 2025-08
$30M
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - HuidaGene Therapeutics
HuidaGene Therapeutics, founded in 2018 and headquartered in Shanghai with a site in New Jersey, is a clinical-stage gene-editing company that discovers and engineers CRISPR/Cas tools (Cas12 DNA editing, Cas13 RNA editing) and develops AAV-delivered therapies for inherited diseases in ophthalmology, neurology, myology and otology. Its HG-PRECISE platform uses machine learning on metagenomic data to discover novel Cas proteins.
— - Syneron Bio
AI-driven synthetic peptide drug developer focused on a pipeline of next-generation synthetic peptide and protein drugs
Series B · $280M · 2026-04
$280M
Europe
BusinessLatest roundTotal raisedDate- Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
— - Amply
AI-accelerated development of gene-silencing therapies for aggressive cancers and inhaled antimicrobials for drug-resistant infections
Seed · $4M · 2025-05
$4M
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.